Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress
19 6월 2020 - 7:15AM
Business Wire
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics
for cancer, today announced the company’s participation in the
European Association for Cancer Research (EACR) 2020 Virtual
Congress, which will be held online, June 18-19, 2020.
Personalis will present “Enabling Composite Biomarker Discovery
for Precision Cancer Therapy with an Enhanced Exome and
Transcriptome Platform“ in an industry-sponsored symposium,
featuring the Personalis universal cancer immunogenomics platform,
ImmunoID NeXT. Erin Newburn, MS, PhD, will present for
Personalis.
Dr. Newburn will provide an overview of how the platform can be
used to explore critical immunotherapy-related resistance
mechanisms and novel composite biomarkers of response utilizing
analytics including human leukocyte antigen (HLA) typing and HLA
loss of heterozygosity (LOH), neoantigen prediction and load,
immune repertoire characterization, and oncoviral detection, as
well as the evaluation of tumor mutational burden (TMB) and
microsatellite instability (MSI) status. In addition, Dr. Newburn
will present a recent case study from a cohort of metastatic
melanoma patients who were treated with an immune checkpoint
blockade, where we integrated several different molecular features
from the ImmunoID NeXT Platform™ to help better define the
responder and non-responder patients.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The Personalis ImmunoID NeXT Platform™
is designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP-aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements
This press release contains or may imply "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements include all statements that are not
historical facts, including, for example, statements regarding the
future availability, features or potential uses of the ImmunoID
NeXT Platform and other future events. These forward-looking
statements are subject to risks and uncertainties, including those
related to the evolution of cancer therapies and market adoption of
our services, our expectations regarding future performance, and
the COVID-19 pandemic, as well as other risks and uncertainties
discussed in Personalis’ filings with the Securities and Exchange
Commission (SEC), including in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic
reports on Forms 10-K and 10-Q and subsequent filings and in the
documents incorporated by reference therein, all of which may
significantly impact our business and operations, the business and
operations of our customers, our ability to access capital and the
value of our common stock. Except as otherwise required by law,
Personalis disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date hereof, whether as a result of new information, future events
or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200618005949/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024